Minireviews
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jan 21, 2023; 29(3): 487-502
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.487
Figure 1
Figure 1 Interplay between coronavirus disease 2019 and metabolic-associated fatty liver disease. COVID-19: Coronavirus disease 2019; MAFLD: Metabolic-associated fatty liver disease; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Figure 2
Figure 2 Selection of coronavirus disease 2019 therapy in metabolic-associated fatty liver disease patient. 1High risk of progression - advanced age ≥ 65-yr-old, immunocompromised state or multiple medical co-morbidities. Hypoxemia: SpO2 ≤ 94% on room air; ECMO: Extracorporeal membrane oxygenation; Mild disease: Cough, upper respiratory tract symptom and absence of dyspnea; Severe: Hypoxemia or need for supplemental oxygen; Moderate: Dyspneic patient and absence of severe disease features. ALT: Alanine transaminase; AST: Aspartate transaminase; COVID: Coronavirus disease; CTP: Child Pugh score; LFT: Liver function test; ULN: Upper limit of normal.